Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tedizolid - Merck & Co

Drug Profile

Tedizolid - Merck & Co

Alternative Names: BAY 1192631; DA-70157; DA-70218; DA-7157; DA-7218; MK-1986; SIVEXTRO; Sivextro; Tedizolid phosphate; Torezolid; Torezolid phosphate; TR-700; TR-701; TR-701 FA; TR-701 free acid

Latest Information Update: 17 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST; Merck & Co
  • Class Anti-infectives; Antibacterials; Fluorinated hydrocarbons; Oxazolidinones; Phosphates; Pyridines; Small molecules; Sodium compounds; Tetrazoles
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Nosocomial pneumonia
  • Phase I Gram-positive infections
  • No development reported Bacteraemia

Most Recent Events

  • 15 Jul 2020 Tedizolid licensed to Nabriva Therapeutics in USA
  • 05 Jun 2020 Merck suspends reinitiates a phase-III trial in Skin and soft tissue infections (In children, In infants) in USA, Turkey, South Africa, Poland, Mexico, Germany, Bulgaria, Brazil (PO) (NCT03176134)
  • 11 May 2020 Merck suspends recruitment in a phase-III clinical trials in Skin and soft tissue infections (In children, In infants) in USA, Turkey, South Africa, Poland, Mexico, Germany, Bulgaria, Brazil (PO) due to COVID-19 pandemic (NCT03176134)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top